|
BUYINS.NET: (SCRX) SqueezeTrigger Price is $19.582. There is
$222,145,872.00 That Short Sellers Still Need To Cover
(M2 PressWIRE Via Acquire Media NewsEdge)
RDATE:09052008
BUYINS.NET / www.squeezetrigger.com is monitoring Sciele Pharma, Inc. -
Common Stock (NASDAQ:SCRX) in real time and just received an alert that
is crossing above its primary SqueezeTrigger Price, the price that a
short squeeze can start in any stock. There are 11287900 shares that
have been shorted at the volume weighted average SqueezeTrigger Price
of $19.582. To access SqueezeTrigger Prices ahead of potential short
squeezes beginning, visit http://www.squeezetrigger.com.
From January 2005 to April 2008, an aggregate amount of 57455295 shares
of SCRX have been shorted for a total dollar value of
$1,091,650,605.00. The SCRX SqueezeTrigger price of $19.582 is the
volume weighted average price that all shorts are short in shares of
SCRX. There is still approximately $222,145,872.00 of potential short
covering in shares of SCRX.
SqueezeTrigger.com has built a massive database that collects, analyzes
and publishes a proprietary SqueezeTrigger Price for each stock that
has been shorted. The data has then been integrated into an automated
trading platform which can be used to connect to a live online broker
and automate your trading of short squeeze events. It is extremely
powerful with lightening fast execution at a very low price. Both the
trading software and SqueezeTrigger data feed are available at
http://www.squeezetrigger.com.
Sciele Pharma, Inc. - Common Stock (NASDAQ:SCRX) Sciele Pharma Inc.,
formerly First Horizon Pharmaceutical Corporation, incorporated in July
1992, is a specialty pharmaceutical company that markets, develops and
sells brand name prescription products. Its key products focus on two
therapeutic categories: Cardiology and Women's Health. The Company
markets and sell 15 products, eight of which are actively promoted and
accounted for approximately 89% of its total sales for the year ended
December 31, 2005. The Company promotes its products through its
nationwide sales and marketing force in approximately 525 territories,
targeting high-prescribing primary care physicians, endocrinologists,
cardiologists, obstetricians and gynecologists. Most of the Company's
products treat recurring or chronic conditions or disorders, which
involve repeated use over an extended period of time.
Sular
In March 2002, it acquired rights to distribute and sell the
antihypertensive prescription medication Sular from AstraZeneca and
Bayer Healthcare in the United States for a period of 10 years. The
Company also entered into a long-term manufacturing, supply and
distribution agreement with Sular's manufacturer, Bayer. Sular is
once-a-day treatment for hypertension that competes in the market for
antihypertensive prescription medications.
Nisoldipine, the active ingredient in Sular, belongs to a group of
medicines called calcium channel blockers. Calcium channel blockers
prevent calcium from entering certain types of muscle cells. Because
the muscle cells need calcium to contract, calcium channel blockers
prevent the cells from contracting and cause them to relax. Nisoldipine
selectively relaxes the muscles of small arteries causing them to
dilate but has little or no effect on muscles or the veins of the heart.
Fortamet and Altoprev
In March 2005, the company licensed and purchased certain rights to the
type 2 diabetes prescription medication Fortamet and the cholesterol
lowering medication Altoprev from Andrx Laboratories. As part of the
transaction, it acquired the worldwide rights to sell Fortamet and
Altoprev. The Company also entered into a long-term manufacturing and
supply agreement with Andrx Laboratories for the manufacture and supply
of Fortamet and Altoprev.
Fortamet is once-a-day extended-release tablet used in the management
of type 2 diabetes. It contains metformin HCl, which is an oral
anti-hyperglycemic drug that has the effect of lowering blood glucose.
Altoprev is once-a-day treatment for high- cholesterol. It consists of
a lovastatin extended-release tablet containing a cholesterol-lowering
agent isolated from a strain of Aspergillus Terreus.
Triglide
It obtained exclusive United States marketing rights, during the year
ended December 31, 2004, to a fenofibrate formulation that employs one
of SkyePharma's proprietary solubilization technologies, which the
Company labeled Triglide. In May 2005, the Company announced that the
United States Food and Drug Administration had approved Triglide, as an
oral treatment for lipid disorders, such as elevated triglycerides.
Triglide is being manufactured and supplied by SkyePharma.
Nitrolingual
In February 2000, it began marketing Nitrolingual for which the Company
acquired exclusive distribution rights in the United States from
Pohl-Boskamp for an initial period of five years and an additional
renewal period of five years. In October 2004, the distribution
agreement was renewed for an additional five years with an additional
renewal period of two years. Nitrolingual is an oral spray of
nitroglycerin used for the acute relief or prevention of chest pain
associated with angina pectoris that results from heart disease.
Pohl-Boskamp holds a patent that expires in 2010 on the formulation of
Nitrolingual that the Company license.
During the second quarter of 2003, it launched a 60-dose application
bottle of Nitrolingual. The 60-dose bottle is smaller and more
convenient to carry for some patients than the Company's 200-dose
bottle.
The SqueezeTrigger database of approximately 1 billion short sale
transactions goes back to January 1, 2005 and calculates the exact
price at which the Total Short Interest is short in each stock. This
data was never before available prior to January 1, 2005 because the
Self Regulatory Organizations (primary exchanges) guarded it
aggressively. After the SEC passed Regulation SHO, exchanges were
forced to allow data processors like SqueezeTrigger.com to access the
data. Total Short Interest is the number of shares shorted but not yet
covered, and is different from total short volume. To access
SqueezeTrigger Prices ahead of potential short squeezes beginning,
visit http://www.squeezetrigger.com
About SQUEEZETRIGGER.COM
WWW.SQUEEZETRIGGER.COM is a service designed to help bonafide
shareholders of publicly traded US companies fight short selling.
SqueezeTrigger.com has built a proprietary database that uses Threshold
list feeds and short sale time and sale data from NASDAQ, AMEX and NYSE
to generate detailed and useful information to combat the short selling
problem. For the first time, actual trade by trade data is available to
the public that shows the attempted size, actual size, price and
average value of short sales in stocks that have been shorted. This
information is valuable in determining the precise point at which short
sellers go out-of-the-money and start losing on their short trades.
SQUEEZETRIGGER.COM has built a massive database that collects, analyzes
and publishes a proprietary SqueezeTrigger for each stock that has been
shorted. The SqueezeTrigger database of nearly one billion short sale
transactions goes back to January 1, 2005 and calculates the exact
price at which the Total Short Interest is short in each stock. This
data was never before available prior to January 1, 2005 because the
Self Regulatory Organizations (primary exchanges) guarded it
aggressively. After the SEC passed Regulation SHO, exchanges were
forced to allow data processors like SqueezeTrigger.com to access the
data.
The SqueezeTrigger database collects individual short trade data on
over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on
nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows
by approximately 50,000,000 short sale transactions and provides
investors with the knowledge necessary to time when to buy and sell
stocks with outstanding short positions. By tracking the size and price
of each month's short transactions, SQUEEZETRIGGER.COM provides
institutions, traders, analysts, journalists and individual investors
the exact price point where short sellers start losing money and a
short squeeze can begin.
All material herein was prepared by SQUEEZETRIGGER.COM, based upon
information believed to be reliable. The information contained herein
is not guaranteed by SQUEEZETRIGGER.COM to be accurate, and should not
be considered to be all-inclusive. The companies that are discussed in
this opinion have not approved the statements made in this opinion.
Occassionally companies pay $995.00 to purchase data for information
provided in reports issued by BUYINS.NET, a company affiliated with
SQUEEZETRIGGER.COM. The data service can be cancelled at any time. This
opinion contains forward-looking statements that involve risks and
uncertainties. This material is for informational purposes only and
should not be construed as an offer or solicitation of an offer to buy
or sell securities. SQUEEZETRIGGER.COM is not a licensed broker, broker
dealer, market maker, investment banker, investment advisor, analyst or
underwriter. Please consult a broker before purchasing or selling any
securities viewed on or mentioned herein. SQUEEZETRIGGER.COM will not
advise as to when it decides to sell and does not and will not offer
any opinion as to when others should sell; each investor must make that
decision based on his or her judgment of the market.
SQUEEZETRIGGER.COM and SQUEEZETRIGGER are intended for use by stock
market professionals. As a member, visitor, or user of any kind, you
accept full responsibilities for your investment and trading actions.
The contents of SQUEEZETRIGGER.COM, including but not limited to all
implied or expressed views, opinions, teachings, data, graphs,
opinions, or otherwise are not predictions, warranty, or endorsements
of any kind. Please seek stock market advice from the proper securities
professional, or investment advisor.
By visiting SQUEEZETRIGGER.COM or using any data or services, you agree
to assume full responsibility for the decisions or actions that you
undertake. Global Automated Trading Systems, LLC, its owner(s),
operators, employees, partners, affiliates, advertisers, information
providers and any other associated person or entity, shall under no
circumstances be held liable to the user and/or any third party for
loss or damages of any kind, including but not limited to trading
losses, lost trading opportunity, direct, indirect, consequential,
special, incidental, or punitive damages. As a user, you agree that any
damages collected shall not exceed the amount paid to
SQUEEZETRIGGER.COM and/or its owners. As a website user, you agree that
any and all legal matters of any kind are to be reviewed and handled in
their entirety within the State of California only. By using the
services of this website, you are consenting to the terms as outlined,
and forfeit all legal jurisdictions in any other State.
Past performance is not a guarantee of future outcomes. Any and all
examples are hypothetical and should not be considered a guarantee or
endorsement of such trading activity. SQUEEZETRIGGER.COM does not take
responsibility for problems of any kind, including but not limited to
issues with operations, data accuracy or completeness, contacting
issues, technical issues, and timeliness. SQUEEZETRIGGER.COM places
great integrity on the data collected and distributed. This information
is deemed reliable, but not guaranteed. All information and data is
provided "as is" without warranty or guarantee of any kind.
Please seek investment and/or trading advice, council, information or
services from a securities professional. You should consider these
factors in evaluating the forward-looking statements included herein,
and not place undue reliance on such statements. The forward-looking
statements in this release are made as of the date hereof and
SQUEEZETRIGGER.COM undertakes no obligation to update such statements.
This release contains "forward-looking statements" within the meaning
of Section 27A of the Securities Act of 1933, as amended, and Section
21E the Securities Exchange Act of 1934, as amended and such
forward-looking statements are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
"Forward-looking statements" describe future expectations, plans,
results, or strategies and are generally preceded by words such as
"may", "future", "plan" or "planned", "will" or "should", "expected,"
"anticipates", "draft", "eventually" or "projected". You are cautioned
that such statements are subject to a multitude of risks and
uncertainties that could cause future circumstances, events, or results
to differ materially from those projected in the forward-looking
statements, including the risks that actual results may differ
materially from those projected in the forward-looking statements as a
result of various factors, and other risks identified in a companies'
annual report on Form 10-K or 10-KSB and other filings made by such
company with the SEC.
SqueezeTrigger is a registered trademark, Reg. No. 3,120,641
CONTACT: Thomas Ronk, CEO, SqueezeTrigger.com
Tel: +1 800 715 9999
e-mail: Tom@SqueezeTrigger.com
WWW: http://www.SqueezeTrigger.com
((M2 Communications Ltd disclaims all liability for information
provided within M2 PressWIRE. Data supplied by named party/parties.
Further information on M2 PressWIRE can be obtained at
http://www.presswire.net on the world wide web. Inquiries to
info@m2.com)).
Copyright ? 2008 M2 Communications Ltd.
[ Back To TMCnet.com's Homepage ]
|
INDUSTRIES
Activate Email 
Find Solutions for Enterprises, SMBs & Service Providers at the INTERNET TELEPHONY Conference and EXPO East, January 20-22, 2010. Miami, FL.
